GlassScriptPhysician profile
Taylor S Davis
NPI 1912747114
$512.63
in general payments reported to CMS, 2019-2025
10 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $56.79 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $143.94 | 2025 | Bimzelx |
| Genzyme Corporation | $118.19 | 2025 | |
| Abbvie INC. | $110.52 | 2025 | |
| Calliditas Therapeutics US INC. | $24.54 | 2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $21.53 | 2025 | Verquvo |
| Viiv Healthcare Company | $20.23 | 2024 | Apretude |
| Pfizer INC. | $19.82 | 2025 | |
| Novo Nordisk INC | $19.42 | 2024 | Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.30 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.14 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.